At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 215 enrolled
Drug / intervention
Netarsudil Ophthalmic Solution 0.01% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
In Brief
A Phase 2 clinical trial evaluating Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, and 2 other interventions for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 215 participants across 25 sites.
Detailed Summary
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionSep 2019
TodayJul 2026
First PostedFeb 19, 2019
Enrollment StartMar 19, 2019
Primary CompletionSep 19, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.4 years ago
Interventions
Netarsudil Ophthalmic Solution 0.01%drug
Topical sterile ophthalmic solution
Netarsudil Ophthalmic Solution 0.02%drug
Topical sterile ophthalmic solution
Netarsudil Ophthalmic Solution 0.04%drug
Topical sterile ophthalmic solution
Netarsudil Ophthalmic Solution Placeboother
Topical sterile ophthalmic solution